Abstract
Pharmaceutical company intelligence reports from Espicom provide a full review
of the company' s activities together with five-year sales forecasts for its
key products. The company' s financial performance is covered in-depth, from
its latest results to a complete analysis of its latest full fiscal year and
an outlook for the future. A section on company strategy covers mergers,
acquisitions and divestitures, key agreements, products and R&D. An overview
of key products and R&D is followed by a comprehensive review of the company' s
product portfolio and research and development pipeline by therapeutic area.
In addition, supplementary appendices provide more in-depth information on
financials, agreements and corporate events.
Table of Contents
EXECUTIVE SUMMARY
A detailed and comprehensive overview of current financial position, company
strategy, product and pipeline analysis.
THERAPEUTIC AREA FOCUS
- Key product analysis and forecasting
- Cardiovascular
- Zanidip/Zanedip (lercanidipine)
- Central Nervous System
- Elopram (citalopram)
- Entact (escitalopram)
- Tradorec XL (tramadol)
- Gastroenterology/Urology
- Peptazol/Ulcotenal (pantoprazole)
- Respiratory
- Exomuc and Hexa (acetylcysteine and biclotimol)
- Anti-Infectives
- Isocef (ceftibuten)
OPERATIONAL DATA
- A wealth of background and detail
- A full 5-year financial performance assessment
- Key agreements
- Infrastructure
- Subsidiaries and joint ventures
| 
